{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:08:31Z","timestamp":1778810911742,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.urolonc.2022.09.016","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T08:52:18Z","timestamp":1667206338000},"page":"166-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2060","authenticated-orcid":false,"given":"Mar\u00eda T.","family":"Melgarejo-Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morales-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaiza","family":"Y\u00e1\u00f1ez-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Arrabal-Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"G\u00f3mez-Lechuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Pareja-V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Juan","family":"Jim\u00e9nez-Mole\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Arrabal","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.09.016_bib0001","unstructured":"Professionals SO. EAU guidelines: non-muscle-invasive bladder cancer [Internet]. Uroweb. [cited 2021 Nov 8]. Available from: https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/."},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0002","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.urolonc.2022.09.016_bib0003","first-page":"5144","article-title":"Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients","volume":"51","author":"Dalton","year":"1991","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.urolonc.2022.09.016_bib0004","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2022.09.016_bib0005","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.7717\/peerj.2309","article-title":"Investigation of the mechanisms of action behind electromotive drug administration (EMDA)","volume":"4","author":"Kos","year":"2016","journal-title":"Peer J"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.016_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000052419","article-title":"Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion","volume":"39","author":"Colombo","year":"2001","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.016_bib0007","first-page":"324","article-title":"Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study","volume":"73","author":"Decaestecker","year":"2018","journal-title":"Acta Clin Belg"},{"issue":"9","key":"10.1016\/j.urolonc.2022.09.016_bib0008","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000502663","article-title":"Intravesical treatment with electro-mediated administration of mytomicin C as prophylaxis for intermediate and high-risk non-muscle-invasive bladder cancer: a retrospective multicenter study","volume":"103","author":"Carando","year":"2019","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.016_bib0011","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.purol.2020.03.005","article-title":"The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: a systematic review","volume":"30","author":"Carando","year":"2020","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.016_bib0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.016_bib0013","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","article-title":"Sequential bacillus Calmette-Gu\u00e9rin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk non-muscle invasive bladder cancer: 2-year outcomes","volume":"195","author":"Gan","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.016_bib0014","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u2018BCG failure\u2019 non muscle invasive bladder cancer: 3\u2009years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2022.09.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of bacillus Calmette-Guerin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade non-muscle invasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.016_bib0016","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.clgc.2020.11.002","article-title":"Second-line conservative device-assisted intravesical treatment in selected patients with recurrent high-risk non-muscle-invasive bladder cancer","volume":"19","author":"Di Gianfrancesco","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.09.016_bib0017","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","volume":"9","author":"Jung","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.016_bib0018","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0022-5347(01)63174-4","article-title":"Intravesical electromotive drug administration technique: preliminary results and side effects","volume":"159","author":"Riedl","year":"1998","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0019","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.016_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.016_bib0022","doi-asserted-by":"crossref","first-page":"e2572","DOI":"10.1097\/MD.0000000000002572","article-title":"Combination of intravesical chemotherapy and bacillus Calmette-Guerin versus bacillus Calmette-Guerin monotherapy in intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"95","author":"Cui","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2022.09.016_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2019.00121","article-title":"Combination of intravesical Bacille Calmette-Gu\u00e9rin and chemotherapy vs. Bacille Calmette-Gu\u00e9rin alone in non-muscle invasive bladder cancer: a meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2022.09.016_bib0024","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/cncr.28731","article-title":"Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer","volume":"120","author":"Bachir","year":"2014","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:22Z","timestamp":1761042442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1078143922003519"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}